All In Biotech

Drug Trial Radar · NCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

286

Actual

Start

Aug 10, 2021

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Tanabe Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Aug 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of oral dersimelagon.

Conditions

  • EPP
  • XLP

Interventions

  • MT-7117Drug

    MT-7117

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]).Time frame: up to 66 further months
  2. Number of patients with abnormal Physical examination dataTime frame: up to 66 further months
  3. Number of patients with Nevi appearanceTime frame: up to 66 further months

Locations

45 sites in 15 countries. Site status is shown where the registry gives one.

  • Marvel Clinical Research, LLC

    Huntington Beach, California

  • University of California at San Francisco - CSF Porphyria Center

    San Francisco, California

  • University Of Miami School Of Medicine, Center For Liver Diseases

    Miami, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • MetroBoston Clinical Partners, LLC

    Brighton, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Kansas City Research Institute

    Kansas City, Missouri

  • Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH)

    New York, New York

  • Wake Forest University Baptist Health

    Winston-Salem, North Carolina

  • Remington-Davis Clinical Research

    Columbus, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • The University of Texas Medical Branch (UTMB)

    Galveston, Texas

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington

  • Wesley Medical Research

    Brisbane, Queensland, Australia

  • Royal Melbourne Hospital (RMH)

    Parkville, Victoria, Australia

  • University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski

    Sofia, Bulgaria

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Institute for Clinical and Experimental Medicine - IKEM

    Prague, Czechia

  • Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre

    Bordeaux, France

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier

    Colombes, France

  • CHU Nantes

    Nantes, France

  • Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine

    Paris, France

  • Charite - Universitaetsmedizin Berlin

    Berlin, Germany

  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia

    Brescia BS, Italy

  • Azienda Sanitaria Ospedaliera Santa Croce E Carle - Cuneo

    Cuneo CN, Italy

  • Ospedalle Galliera

    Genova GE, Italy

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy

  • U.O.C. Medicina Interna Azienda ospedaliero Universitaria Policlinico di Modena

    Modena, Italy

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Materno-Infantile - Burlo Garofolo - Clinica Pediatrica

    Trieste TS, Italy

  • I.F.O. Hospital, Centro Porfirie e Malattie Rare

    Roma, Rome, Italy

  • Hamamatsu University Hospital

    Shizuoka, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • Sophia Dermatology Clinic

    Kanazawa, Ishikawa-ken, Japan

  • Osaka Medical College Hospital

    Takatsuki, Osaka, Japan

  • Tokyo Saiseikai Central Hospital

    Minato-ku, Tokyo, Japan

  • Toyama University Hospital

    Sugitani, Toyama, Japan

  • Erasmus MC, Universitair Medisch Centrum Rotterdam

    Rotterdam, Netherlands

  • Haukeland University Hospital

    Bergen, Norway

  • Instytut hematologii i Transfuzjologii

    Warsaw, Poland

  • Hospital Clínic de Barcelona

    Barcelona, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.